CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.
Niacin Extended-Release/Simvastatin: Simcor
| Study Name | |||
|---|---|---|---|
| M10-013 | Cholesterol Lowering | Phase 3 | SUPREME: A 12-week, Open-label, Multicenter Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia |